Behavioural Brain Research
July 1, 2022
Li-Min Zhang, Na Liu, Lucy Cao et al.
BACKGROUND Anesthesia and psychotropic drugs in pregnant women may cause long-term effects on the brain development of unborn babies. The authors set out to investigate the neurotoxicity of S-ketamine, which possesses anesthetic and antidepressant effects and may cause attention deficit hyperactivity disorder (ADHD)- and depression-like behaviors in offspring mice. METHODS Pregnant mice were...
Journal of Studies on Alcohol and Drugs
July 1, 2022
Timothy I. Michaels, Lebert Lester, Sara de la Salle et al.
19 citations
OBJECTIVE: Despite strong evidence for the safety and efficacy of ketamine in the treatment of mood disorders, the enrollment of Black, Indigenous, and People of Color (BIPOC) has not been a focus of this research. Health disparities in the treatment of mood disorders in BIPOC indicate a strong need to understand the clinical, social, and pharmacological aspects of this novel treatment in...
Iranian Journal of Psychiatry
July 1, 2022
Ahmad Shamabadi, Ali Ahmadzade, Ali Aqamolaei et al.
Objective: Available treatments of depression have limited efficacy and unsatisfactory remission rates. This study aims to review randomized controlled trials (RCTs) investigating effects of glutamate receptor modulators in treating patients with resistant depression. Method : The study protocol was registered in PROSPERO (CRD42021225516). Scopus, ISI Web of Science, Embase, Cochrane Library,...
Journal of Affective Disorders
July 1, 2022
Thomas D Hull, Matteo Malgaroli, Adam Gazzaley et al.
59 citations
BACKGROUND At-home Ketamine-assisted therapy (KAT) with psychosocial support and remote monitoring through telehealth platforms addresses access barriers, including the COVID-19 pandemic. Large-scale evaluation of this approach is needed for questions regarding safety and effectiveness for depression and anxiety. METHODS In this prospective study, a large outpatient sample received KAT over...
Scientific Reports
June 30, 2022
Jacopo Lamanna, Francesco Isotti, Mattia Ferro et al.
Unpredictable chronic mild stress (CMS) is among the most popular protocols used to induce depressive-like behaviors such as anhedonia in rats. Differences in CMS protocols often result in variable degree of vulnerability, and the mechanisms behind stress resilience are of great interest in neuroscience due to their involvement in the development of psychiatric disorders, including major...
Molecular Psychiatry
June 27, 2022
Gustavo C Medeiros, T. Gould, W. Prueitt et al.
(R,S)-ketamine (ketamine) and its enantiomer (S)-ketamine (esketamine) can produce rapid and substantial antidepressant effects. However, individual response to ketamine/esketamine is variable, and there are no well-accepted methods to differentiate persons who are more likely to benefit. Numerous potential peripheral biomarkers have been reported, but their current utility is unclear. We...
Frontiers in Pain Research
June 27, 2022
Dianna E. Willis, Peter A. Goldstein
6 citations
The phencyclidine-derivative ketamine [2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one] was added to the World Health Organization's Model List of Essential Medicines in 1985 and is also on the Model List of Essential Medicines for Children due to its efficacy and safety as an intravenous anesthetic. In sub-anesthetic doses, ketamine is an effective analgesic for the treatment of acute pain...
Neurology International
June 23, 2022
Islam Mohammad Shehata, Waniyah Masood, Nouran Nemr et al.
41 citations
Depression is a leading cause of disability globally, with a prevalence of 3.8% among the whole population, 5% of the adult population, and 5.7% of the elderly population over 60 years of age. There is evidence that depression is linked to certain neurodegenerative diseases, one being Alzheimer’s disease (AD). The efficacy of conventional antidepressants to treat depression in AD is...
Frontiers in Behavioral Neuroscience
June 21, 2022
Caitlyn J Bartsch, Jacob C. Nordman
Treatment options for chronically aggressive individuals remain limited despite recent medical advances. Traditional pharmacological agents used to treat aggression, such as atypical antipsychotics, have limited efficacy and are often replete with dangerous side effects. The non-competitive NMDAR antagonists ketamine and memantine are promising alternatives, but their effects appear to be...
Biomedicines
June 21, 2022
Andrea Zemba Čilić, M. Zemba, M. Cilic et al.
We attempted throughout the NO-system to achieve the particular counteraction of the ketamine-induced resembling “negative-like” schizophrenia symptoms in rats using pentadecapeptide BPC 157, and NO-agents, NG-nitro-L-arginine methylester (L-NAME), and/or L-arginine, triple application. This might be the find out the NO-system organized therapy (i.e., simultaneously implied NO-system blockade...
International Journal of Molecular Sciences
June 16, 2022
Adam Wojtas, Agnieszka Bysiek, Agnieszka Wawrzczak-Bargieła et al.
110 citations
Clinical studies provide evidence that ketamine and psilocybin could be used as fast-acting antidepressants, though their mechanisms and toxicity are still not fully understood. To address this issue, we have examined the effect of a single administration of ketamine and psilocybin on the extracellular levels of neurotransmitters in the rat frontal cortex and reticular nucleus of the thalamus...
bioRxiv Preprint Server
June 12, 2022
Luciana López-Jury, Francisco García-Rosales, Eugenia González-Palomares et al.
preprint
Although new advances in neuroscience allow the study of vocal communication in awake animals, substantial progress in the processing of vocalizations has been made from brains of anaesthetized preparations. Thus, understanding how anaesthetics affect neuronal responses is of paramount importance. Here, we used electrophysiological recordings and computational modelling to study how the...
Journal of Neurochemistry
June 9, 2022
Vern Lewis, Brandon Rodrigue, Emma J. Arsenault et al.
Ketamine has shown antidepressant effects in patients with major depressive disorder (MDD) resistant to first‐line treatments and approved for use in this patient population. Ketamine induces several forms of synaptic plasticity, which are proposed to underlie its antidepressant effects. However, the molecular mechanism of action directly responsible for ketamine's antidepressant effects...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
June 8, 2022
Weam W Ibrahim, R. H. Sayed, Esraa A Kandil et al.
Dysregulated inflammatory responses and blood-brain barrier (BBB) dysfunction are recognized as central factors in the development of psychiatric disorders. The present study was designed to evaluate the effect of niacin on BBB integrity in ketamine-induced model of psychosis. Meanwhile, mepenzolate bromide (MPN), a GPR109A receptor blocker, was used to investigate the role of this receptor on...
European Psychiatry
June 1, 2022
M. Barbosa, R. Guedes
IntroductionEsketamine is an S-enantiomer of ketamine approved by the EMA for treatment-resistant depression (TRD). As an NMDA receptor antagonist, its administration results in increase of glutamate release and AMPA receptor activation, supporting both rapid-onset and long-term antidepressant effects. Short-term tolerability seems acceptable but major concerns remain regarding long-term...
Fundamental and Clinical Pharmacology
June 2022
Jules Baudot, Thomas Soeiro, Marine Tambon et al.
Prominent features of esketamine (e.g., similar mechanism of action as ketamine and target population) require to be vigilant regarding its benefits/risks balance and its risks of abuse in real-life settings. The aim of this study was to review all available pharmacological and clinical data to assess the abuse potential of esketamine shortly after its marketing. This multidimensional study is...
Neuroscience & Biobehavioral Reviews
June 1, 2022
Xingming Wang, Jianjun Yang, Kenji Hashimoto
Neurological disorders are the leading cause of disability and the second leading cause of death worldwide. The increasing social and economic burdens of neurological disorders are driven by global population growth and aging. Depression is a common psychiatric symptom in numerous neurological disorders. It is also a risk factor for Alzheimer's disease (AD) and other dementias, Parkinson's...
Behavioural Pharmacology
June 1, 2022
José Eduardo Suárez-Santiago, Gabriel Roldán Roldán, Ofir Picazo Picazo
Schizophrenia is a serious mental disorder that affects 1% of the world’s population. Although various therapeutic tools have been developed since the appearance of the first generation of antipsychotics, the effect of these agents does not manage to attenuate a significant part of psychotic symptoms. Ketamine is an anesthetic agent able to produce psychotic-like symptoms through the antagonism...
Biological Psychiatry
June 1, 2022
Yukitoshi Izumi, F. Hsu, C. Conway et al.
BACKGROUND: Nitrous oxide (N2O) is a non-competitive inhibitor of NMDA receptors (NMDARs) that appears to have ketamine-like rapid antidepressant effects in patients with treatment resistant major depression. In preclinical studies, ketamine enhances glutamate-mediated synaptic transmission in hippocampus and prefrontal cortex. The present study examined effects of N2O on glutamate transmission...
Anesthesia & Analgesia
June 1, 2022
Michael A. Brito, Duan Li, Christopher W Fields et al.
Neurophysiologic complexity has been shown to decrease during states characterized by a depressed level of consciousness, such as sleep or anesthesia. Conversely, neurophysiologic complexity is increased during exposure to serotonergic psychedelics or subanesthetic doses of dissociative anesthetics. However, the neurochemical substrates underlying changes in neurophysiologic complexity are...